Recurrent Vulvovaginal Candidiasis (RVVC) Emerging Therapy and TPP Insights

Thelansis’s “Recurrent Vulvovaginal Candidiasis (RVVC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Recurrent Vulvovaginal Candidiasis (RVVC) Overview

Recurrent vulvovaginal candidiasis is a chronic gynecological condition defined by repeated episodes of Candida infection, usually four or more within a year. The majority of cases are caused by Candida albicans, but non‑albicans species such as Candida glabrata are increasingly reported and can be more resistant to standard antifungal drugs. Women affected experience cycles of itching, burning, irritation, and discharge that significantly impact daily life and well-being. While risk factors such as diabetes, frequent antibiotic use, hormonal changes, and immune imbalance can contribute, many women develop RVVC without a clear underlying cause. Diagnosis requires confirmation of Candida species through culture or molecular testing, particularly to identify resistant strains. Long‑term management often involves extended antifungal therapy, typically fluconazole, but relapse and resistance remain common. Because durable control is challenging to achieve, RVVC is recognized as a critical unmet need in women’s health, driving research into new antifungal agents, immunotherapies, and preventive vaccines.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)